KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-Current Deffered Revenue: 2009-2025

Historic Non-Current Deffered Revenue for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to $107.9 million.

  • Ionis Pharmaceuticals' Non-Current Deffered Revenue fell 37.91% to $107.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.9 million, marking a year-over-year decrease of 37.91%. This contributed to the annual value of $156.5 million for FY2024, which is 35.11% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Non-Current Deffered Revenue of $107.9 million as of Q3 2025, which was down 13.74% from $125.1 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Non-Current Deffered Revenue peaked at $402.0 million during Q1 2021, and registered a low of $107.9 million during Q3 2025.
  • For the 3-year period, Ionis Pharmaceuticals' Non-Current Deffered Revenue averaged around $193.2 million, with its median value being $188.7 million (2024).
  • Data for Ionis Pharmaceuticals' Non-Current Deffered Revenue shows a maximum YoY crashed of 37.91% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' Non-Current Deffered Revenue stood at $351.9 million in 2021, then decreased by 18.22% to $287.8 million in 2022, then dropped by 16.19% to $241.2 million in 2023, then plummeted by 35.11% to $156.5 million in 2024, then tumbled by 37.91% to $107.9 million in 2025.
  • Its Non-Current Deffered Revenue stands at $107.9 million for Q3 2025, versus $125.1 million for Q2 2025 and $140.7 million for Q1 2025.